Folate receptor-targeted ultrasonic PFOB nanoparticles: Synthesis, characterization and application in tumor-targeted imaging

KESHI LI1*, YAHUI LIU1*, SHENGMIN ZHANG1, YOUFENG XU1, JIANSHUAI JIANG1, FENGYING YIN1, YUE HU1, BAOSAN HAN2, SHUXIONG GE3, LI ZHANG3 and YONG WANG1

1Department of Hepatobiliary Surgery, Ningbo First Hospital, Haishu, Ningbo, Zhejiang 315010; 2Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Yangpu, Shanghai 200092; 3Ningbo Medical School of Ningbo University, Jiangbei, Ningbo, Zhejiang 315211, P.R. China

Received February 23, 2016; Accepted April 24, 2017

DOI: 10.3892/ijmm.2017.2975

Abstract. In this study, we aimed to determine an effective strategy for the synthesis of folate receptor (FR) targeted-nanoparticles (FRNPs). The nanoparticles used as ultrasound contrast agents (UCAs) were composed of a liquid core of perfluorooctyl bromide (PFOB) liposome and a targeted shell chemically conjugated with folic acid (FA) and polyethylene glycol (PEG). This was done in order to avoid recognition and clearance by the mononuclear phagocyte system [also known as the reticuloendothelial system (RES)] and enhance the targeting capability of the nanoparticles to tumors overexpressing folate receptor (FR). The FRNPs exhibited an average particle size of 301±10.8 nm and surface potential of 39.1±0.43 mV. Subsequently, in vitro, FRNPs labeled with FITC fluorescence dye were visibly uptaken into the cytoplasm of FR-overexpressing cancer cells (Bel7402 and SW620 cells), whereas the A549 cells expressing relatively low levels of FR just bound with few FRNPs. These results demonstrated that FRNPs have a high affinity to FR-overexpressing cancer cells. Additionally, in vivo experiments, FRNPs achieved a greater enhancement of tumor ultrasound imaging and a longer enhancement time in FR-overexpressing tumors and the Cy7-labeled FRNPs exhibited a relatively high tumor-targeted distribution in FR-overexpressing tumors. Targeted ultrasound and fluorescence imaging revealed that FRNPs have the ability to target FR-overexpressing tumors and ex vivo fluorescence imaging was then used to further verify and confirm the presence of FRNPs in tumor tissues with histological analysis of the tumor slices. On the whole, our data demonstrate that the FRNPs may prove to be a promising candidate for the early diagnosis for FR-overexpressing tumors at the molecular and cellular levels.

Introduction

Ultrasound contrast agents (UCAs) are widely used in clinical practice in order to enhance the diagnostic capability and utility of traditional ultrasound imaging modes. The UCAs currently used commercially are usually designed to serve as blood pool agents with diameters of 1-8 µm and cannot pass through the blood vessel wall into the tumor tissue to achieve the molecular imaging of tumor tissue (1). Additionally the vascular endothelial gap in tumors is approximately 380-780 nm, which is much wider than that of normal tissue (2,3). In order to ensure that UCAs pass through the tumor tissue, researchers have paid more attention to the preparation of nanosized UCAs, due to their potential for the extravascular molecular imaging of tumors (4).

Although nanosized UCAs achieve passive imaging for tumors via enhanced permeability and retention (EPR), the specific capability of nanosized UCA to bind with tumor tissue is still limited (5). The technique which involves labeling nanoparticles with specific ligands can generate targeted nanoparticles capable of binding to specific tissues or tumors (6-8). Following intravenous injection, the nanoparticles aggregate specifically in the target tissues via the blood circulation, thus allowing the ultrasonography-based specific imaging of pathogenic changes at a molecular or cellular level (9).

Folate receptor (FR) binds folic acid (FA) with high affinity and mediates its intracellular transport via receptor-mediated endocytosis (10). There are three isoforms of FR (FRα, FRβ and FRγ) and type α is the major isoform mediating folate transport, and is overexpressed on the surface of various types of tumor, including pancreatic, prostate, lung, head and neck, breast and ovarian cancer, and mesothelioma (11-19). Based on its limited expression and restricted distribution pattern in normal tissue, FRα is the most widely studied member of the...
FR family, and various strategies for targeting FR, which is overexpressed in cancer, have been developed (20,21). However, very few techniques involving ultrasound nanoparticles coupled with FR targeting and layer-by-layer (LbL) self-assembly have been described, to the best of our knowledge (22,23). In the present study, we developed nanosized and highly efficient targeted nanoparticles modified with FA and polyethylene glycol (PEG) to verify the hypothesis that targeted nanoparticles can enhance the diagnostic value of ultrasound in FR-overexpressing tumors.

Materials and methods

Materials. N-Hydroxysuccinimide (NHS) were supplied by Sinopharm Chemical Reagent (Shanghai, China). Perfluoroctyl bromide (PFOB), FA and N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) were obtained from Sigma-Aldrich (St. Louis, MO, USA). PEG (NH₂-PEG₃₅₀₀) was obtained from Xibao Biochemicals (Shanghai, China). Chitosan (CS; degree of deacetylation 95%) was obtained from Haidebei Marine Bioengineering (Shandong, China). Alginate (ALG) was obtained from Yuanye Biotech (Shanghai, China). Anti-folate binding protein antibody (EPR4708) was obtained from Abcam (Cambridge, UK). Fluorescein isothiocyanate (FITC), DiI and immobilon-P transfer membrane were purchased from Solarbio (Beijing, China). Cy7 NHS ester (MW 720.94) was obtained from FANBO Biochemicals (Beijing, China). The PrimeScript™ RT reagent kit with gDNA eraser and SYBR Green I (MW 600.15) was obtained from Solarbio (Beijing, China). Cy7 NHS ester (MW 720.94) was obtained from FANBO Biochemicals (Beijing, China). The PrimeScript™ RT reagent kit with gDNA eraser and SYBR Green I (MW 600.15) was obtained from Solarbio (Beijing, China).

Cell culture and animal preparation. Bel7402 (human liver cancer cells), SW620 (human colorectal cancer cells) and A549 (human lung cancer cells) were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). BALB/c 3T3 fibroblasts were purchased from the Cell Bank of Zhongshan University (Guangzhou, China). The cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C, 5% CO₂, and kept in a specific pathogen-free environment. 

Detection of FR expression in 3 types of cancer cells and xenografts

FR mRNA expression in cancer cell lines detected by reverse transcription-quantitative PCR (RT-qPCR). RT-qPCR was used to measure the mRNA expression of FRα in the 3 types of cancer cells using TRIzol reagent protocol (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed using 500 ng of total RNA and the PrimeScript™ RT reagent kit according to the manufacturer's instructions, and PCR was performed using the following primers: human FRα (sense strand, 5'-AGGTGCCATCTCTCCACAGT-3' and antisense, 5'-GAGGACAGTGTCATGAGCA-3'; cDNA amplicon size: 135 bp; Tm, 60°C); human GAPDH (sense, 5'-TTTAAAGCAGCCCTGGTGAC-3' and antisense, 5'-CTCTGCTCTCCTGTTGCAC-3'; cDNA amplicon size: 138 bp; Tm, 60°C). cDNA was measured by using SYBR-Green RT-PCR in a StepOnePlus Real-Time PCR system (Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 95°C for 30 sec, 40 cycles of 95°C for 5 sec and 60°C for 34 sec. All PCR reactions were performed at least in triplicate and the mRNA levels were represented as relative quantification, which was calculated using relative expression of FR (NFRα) = 2^(-ΔΔCq), where Cq = ΔCq sample - ΔCq calibrator (ΔCq = Cq of target gene - Cq of GAPDH).

Western blot analysis and immunohistochemical staining of FR in tumor tissues. Each tumor xenograft tissue (300 mg) was lysed by ice for 30 min in 1 ml radiolabeled cell lysis buffer (RIPA) followed by the addition of 10 µl PMSF. All tumor tissue lysates were then transferred into a 1.5 ml tube and centrifuged for 15 min at 15,000 rpm at 4°C. The supernatant was transferred to a new 1.5 ml centrifuge tube. A bicinechonic acid (BCA) kit (ComWin Biotech, Beijing, China) was then used to determine the protein concentration. Additionally, the samples were supplemented with 5X sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer, mixed and boil for 5 min. Twenty micrograms of total protein were separated by SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% albumin bovine in TBST at room temperature for 1 h. Subsequently the blots were incubated with 1:5,000 dilution (0.145 µg/ml) anti-folate binding protein monoclonal antibody (EPR4708; ab125030; Abcam) at 4°C overnight, followed by the addition of 1:500 dilution of goat anti-rabbit IgG HRP-conjugated secondary antibody (CW0103S; ComWin Biotech) at room temperature for 2 h; the membrane was washed 3 times with TBST after each antibody incubation.

To detect FR expression by immunohistochemical staining, each tumor-bearing nude mouse was anesthetized intraperitoneally with 1% sodium pentobarbital and sacrificed when the subcutaneous tumors reached the required volume. After that, the tumors were completely removed from the xenografts and frozen by liquid nitrogen immediately. The fresh frozen blocks of the removed tumors were dissected into serial sections of approximately 4-µm-thick using a freezing microtome (CM1860; Leica Microsystems, Wetzlar, Germany). Each section was covered on a clean glass slide and fixed by 4% paraformaldehyde for 10 min. The slides were then washed in phosphate-buffered saline (PBS), and soaked in 3% hydrogen peroxide methanol solution for 15 min. Each slide was incubated
with 5% goat serum albumin for 20 min to block non-specific antigen sites, and rabbit anti-folate binding protein monoclonal antibody (EPR4708; ab125030; Abcam) was added. These slides were placed inside a humidified chamber for 30 min at room temperature, then washed with PBS buffer for 5 min and dried. Subsequently, the streptavidin-biotin complex immunocytochemistry protocol was used for staining and mild re-dyeing with hematoxylin. Subsequently, the slides were dehydrated, covered slipped with mounting, and observed under a microscope (NIB-100; Olympus, Tokyo, Japan). The results were considered as positive when claybank particles were observed in the cytoplasm, cell membrane or nucleus.

Preparation of FR-targeted nanoparticles (FRNPs) and blank nanoparticles (NPs). The FR-targeted PFOB (FRNPs) were prepared to combine FA- and PEG-modified targeted shells with a PFOB nanocore template using the LbL assembly technology. PFOB nanocore templates were prepared by thin-film hydration and the ultrasonic emulsification method, as previously described (24,25). Firstly, egg lecithin and cholesterol (2:1 M ratio) were dissolved into an organic solvent mixture of chloroform. The organic solvent was removed from the organic mixture in an rotary evaporator (Yarong, Shanghai, China) at 50˚C under a vacuum. The resulting thin film (100 mg) was hydrated by using purified water (5 ml) and then alginate (100 mg) was added to the solution. Subsequently, the mixture was supplemented with PFOB (220 µl) in a dropwise manner and sonicated at a certain ultrasound intensity to form the PFOB nanocore template. The resulting PFOB nanocore templates also served as blank NPs for use in subsequent experiments.

FA conjugation to CS and ALG modified with NH₂-PEG were carried out to form crosslinking between amino and carboxyl groups in the presence of EDC and NHS, which served as targeted shells, as previously described (23). Briefly, the synthesis of FA-CS was as follows: FA (220.7 mg) dissolved in 10 ml of DMSO was activated with EDC (287.6 mg) and NHS (172.6 mg) at room temperature for 4 h, and the activated solution was then added in a dropwise manner to 20 ml of 2% acetic acid aqueous solution containing CS (161 mg) and stirred for 20 h at room temperature in the dark. Also, the synthesis of PEG-ALG was as follows: ALG (176 mg) dissolved in 10 ml of DMSO was activated with EDC (46 mg) and NHS (27.6 mg) at room temperature for 4 h, then the activated solution was then added in a dropwise manner to 20 ml of 2% acetic acid aqueous solution containing PEG (273.2 mg) and stirred for 20 h at room temperature in the dark. The reaction products were dialyzed using dialysis membrane (molecular weight cut-off of 8-10 kDa) to remove unreacted substance and lyophilized.

Polymer (FA-CS and PEG-ALG) and PFOB liposome solutions were prepared at a concentration of 10 mg/ml and 30 mg/ml. Subsequently, 1 ml polymer (FA-CS) solution was added to the liposome dispersions and vortexed for 10 min. The mixture was then sonicated for 5 min and kept aside for PEG-ALG polymer solution addition (26). The above steps were repeated 3 times and the resulting products were incubated with 2 ml polymer (FA-CS) solution for 30 min. The FRNPs were then obtained by centrifugation (12,000 x g, 10 min, 4˚C) and washed 3 times using purified water. The FRNPs was dispersed in 5% w/v mannitol aqueous solution by low-frequency ultrasound and filtrated by 0.45 µm membrane filtration to remove large impurities.

Characterization of nanoparticles

Particle size and zeta potential. Firstly the appearance of FRNP emulsions was observed using a light microscope (NIB-100; Olympus). Particle size, polydispersity index (PDI) and zeta potential were obtained using a Malvern Zetasizer Nano ZS (Malvern Instrument, Malvern, UK) and size measurements were performed at 20°C. The results were expressed as the mean diameter and size distribution of FRNPs, blank NPs obtained from 3 measurements. The standard deviation of the size and the PDI were also given. Before each measurement, 200 µl of nanoparticles suspension were diluted into 1 ml of PBS.

Transmission electron microscopy (TEM). The morphological characterization and internal structure of FRNPs and blank NPs were observed using a transmission electron microscope JEOL 2100 HR (Jeol, Tokyo, Japan). Suspensions of FRNPs and blank NPs were deposited on filter papers to blot off the excess solution and air-dried by using an incandescent lamp before observation. Images were acquired using a high-resolution camera, Advantage Orius 831 (Gatan, Pleasanton, CA, USA).

Targeted binding assay of nanoparticles in vitro. Logarithmic-phase Bel7402, SW620 and A549 cells were stained with DIL before use. The stained cells were then seeded on coverslips placed in 12-well cell plates at a density of 2x10⁴ cells/well divided into 2 groups and cultured for 24 h. FITC-labeled FRNPs (1x10⁴ particles/ml, 20 µl) were added to the first group, which served as the targeted group. FITC-labeled blank NPs (1x10⁴ particles/ml, 10 µl) were added to the second group, which served as the control group. After the cells were incubated with the nanoparticles for 6 h, the coverslips were washed 3 times with PBS, fixed with 4% paraformaldehyde and finally washed with PBS. Subsequently, the coverslips were mounted onto glass slides and observed under a fluorescence microscope (DMIRB; Leica Microsystems).

Ultrasound targeted imaging of FRNPs in vivo. Nine animals were used for each xenograft tumor type in ultrasound imaging. The tumor-bearing nude mice were anesthetized intraperitoneally with 1% sodium pentobarbital for imaging, and the surfaces of both the tumor and probe were covered with a 6-mm-thick coupling agent. A LA332 broadband linear ultrasound probe connected to an Mylanb90 ultrasound system (Esaote, Genova, Italy) was used to perform B mode ultrasound imaging of the xenografts. Once the cross-section of a xenograft was fully observed, the probe was immobilized and the parameters of ultrasonography mode were set up (mechanical index 0.7; gain 80%). Each type of test tumor-bearing nude mice were divided into 3 groups: group A received 200 µl FRNPs, group B received 200 µl blank NPs and group C received 200 µl Sonovue. The contrast agents were injected into the test animals via the tail vein. The ultrasound images of the xenografts were collected prior to the injection and at 1, 5, 10, 20, 40, 80, 120 and 160 min post-injection; the imaging date were collected to calculate the increased imaging intensity at different time-points.

Fluorescence imaging of FRNPs in vivo. To validate the targeting capability of FRNPs in the other routine and investigate the biodistribution of FRNPs, we labeled the shell of FRNPs with Cy7 fluorescent dye (27) and each xenograft was intravenously injected with 200 µl Cy7-labeled FRNPs. Six animals were used...
for each type of xenograft. Following administration by intravenous injection, the time-dependent biodistribution of the FRNPs in the xenografts was imaged using the Kodak In-vivo Imaging System FX Pro (excitation, 610 nm; emission, 790 nm; exposure time, 10 sec; Carestream Health, Rochester, NY, USA). The fluorescence images were then analyzed based on their spectral patterns using Carestream Molecular Imaging software. Scans were performed at 5, 30 min, 1, 1.5, 3 and 12 h post-injection, after which the tumor-bearing mice were sacrificed. The tumors, heart, liver, spleen, lungs, kidneys and intestines were harvested and imaged to estimate the tissue distribution of FRNPs. To compare the targeting ability of FRNPs in different tumors, the target-to-background ratio (TBR) at different time points was obtained using the Carestream MI software to calculate regions of interest (ROI) functions. The ROIs were selected manually by drawing regions on the in vivo fluorescent images. The TBR was calculated using the following formula: 

\[ \text{TBR} = \frac{\text{SI}_T}{\text{SI}_M} \]

where \( \text{SI}_T \) is the average signal intensity of the tumor and \( \text{SI}_M \) is the average signal intensity of the contra lateral thigh muscle. This procedure was carried out as previously described by Alencar et al (28).

Statistical analysis. The experimental data were analyzed using Statistical Package for Social Science (SPSS) 19.0 software (SPSS Inc., Chicago, IL, USA). All the quantitative data were expressed as the means ± standard deviation. The FRNPs and blank NB ultrasound indicator data from in vivo imaging were obtained and analyzed using Image-Pro Plus 6.0 software (Media Cybernetics Inc., Rockville, MD, USA). The ultrasound indicators of the nanoparticles in the 3 types of xenografts were analyzed by analysis of variance (ANOVA). A P-value <0.05 was considered to indicate a statistically significant difference. Histograms and the curve with non-linear regression were plotted using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA).

Results

Synthesis of the nanoparticles. In this study, we used PFOB as the core of the contrast agents, which is a classical, highly biocompatible alternative for nanosized ultrasound contrast agents. The synthesis of PEG-ALG and FA-CS was conducted using the carbodiimide method. Furthermore, we attempted to develop FR-targeted PFOB nanoparticles enveloped in a targeted shell consisting of PEG-ALG and FA-CS and explored the related characteristics, targeting ability, biodistribution in vivo and ultrasound contrast-enhancing potential and behavior. The process of LbL self-assembly is shown in Fig. 1.

Histological analysis. Twelve animals (each type of xenografts taken from 4 mice) were divided into 2 groups, including the targeted group and the control group. The targeted group was intravenously injected with 200 µl Cy7-labeled FRNPs, whereas the control group received 200 µl physiological saline. At 2 h post-injection, the mice were sacrificed. Tumor tissues were carefully removed and fixed with 4% paraformaldehyde at pH 7.4 for 4 days. The tumors were then washed with PBS, then embedded with optimal cutting temperature (OCT) and placed into liquid nitrogen for storage. Frozen tissue blocks were dissected into 4-μm-thick sections and placed on clean glass slides. The slides were dehydrated, coverslipped and mounted, and examined under a fluorescence microscope (DMIRB; Leica Microsystems). Red fluorescence spots were observed with a long-pass 515-560 nm emission filter.

Particle size and zeta potential characterization. The data of dynamic light scattering (DLS) analysis indicated that the alternate polymer assembly was accompanied by a gradual
mice and determined FR expression in the tumor tissue of these with these cancer cell lines by injecting the cell suspensions into 

Subsequently, we developed certain types of tumor xenografts 

cells. The A549 cells exhibited the lowest expression level of FR. 

showed that among these 3 types of cancer cells, the Bel7402 

SW620 and A549 cancer cells. The results presented in Fig. 3A 

RT-qPCR was used to examine FR expression in the Bel7402, 

Establishment of tumor xenograft animal model. Firstly, 

3 types of xenografts (for each type of xenograft, we randomly selected 3 animals).

The results of western blot analysis (Fig. 3B) and immuno-

histochemical staining (Fig. 3C) of the tumor tissues were 

consistent with the results of RT-qPCR for the FR mRNA level in the 3 cancer cell lines. FR expression in the Bel7402 and SW620 tumor xenografts was much higher than that in the A549 tumor xenografts. This indicated that the animal models were successfully created and that the xenografts conformed to the requirement for the experiments of ultrasound targeted imaging and biodistribution in vivo.

Uptake of nanoparticles by the cancer cells. Since the FITC-
labeled FRNPs and blank NPs were developed to bind to FR and trigger receptor-mediated internalization in tumor cells, we compared the uptake of the targeted group and the control group in the Bel7402 cells, SW620 cells and A549 cells lines (Fig. 4). In the targeted group, a large number of green fluorescent spots representing the FRNPs were absorbed into the cytoplasm of Bel7402 and SW620 cells, whereas few green spots remained on the cell membrane of the A549 cells. Furthermore, in the control group, few green fluorescent spots representing the blank NPs were also observed on the 3 types of cell membrane. These results demonstrated that the FRNPs had a greater affinity to the Bel7402 cells and SW620 cells, in which FR was overexpressed.

Ultrasound targeted imaging in vivo

The peak enhancement of tumor ultrasound imaging results. The peak enhancement of tumor imaging is shown in Fig. 5. The ultrasonographic images among the 3 types of xenografts revealed that the enhancement of Sonovue was higher than the enhancement achieved with the FRNPs and blank NPs. However, the enhancement of the FRNPs in both the Bel7402 and SW620 tumor xenografts was apparently higher than the enhancement achieved with the blank NPs at the peak level. In the A549 tumor xenografts, the imaging results of the FRNPs and blank NPs were comparable at the peak level of enhancement. Thus, the blank NPs achieved the worst performance on tumor-enhanced imaging, and both the FRNPs and Sonovue obtained excellent tumor-enhanced imaging for FR overexpressing tumors.

Variation trend in the intensity value of tumor-enhanced imaging. Imaging Pro Plus 6.0 software was used to analyze the grey value of the ultrasound images. The difference in the grey valve of images collected at pre-injection and post-injection served as the intensity value of tumor imaging by 3 types of contrast agents in the xenografts. The time-intensity curve is shown in Fig. 6, illustrating the change in ultrasonic enhancement in areas of interest (AOI) of the tumors collected from the xenografts. From 1 to 10 min post-injection, the intensity value of tumor imaging by 3 types of FRNPs and blue NPs were comparable at the peak level of enhancement achieved with the FRNPs and blank NPs. The enhancement of Sonovue was higher than the enhancement achieved with the blank NPs at the peak level. In the A549 tumor xenografts, the imaging results of the FRNPs and blank NPs were comparable at the peak level of enhancement. Thus, the blank NPs achieved the worst performance on tumor-enhanced imaging, and both the FRNPs and Sonovue obtained excellent tumor-enhanced imaging for FR overexpressing tumors.

increase in particle size (Fig. 2A). Prior to LbL fabrication, 

blank NPs (PFOB liposomes) exhibited an average particle size of 196.2±9.3 nm. In the LbL assembly process, the overall size of the nanoparticles decreased after each addition of PEG-ALG. This indicated that the strong ionic electrostatic interaction between PEG-ALG and FA-CS contributed to the formation of a mesh shell on the surface of PFOB liposome. After the process was completed, the final size of the FRNPs reached an average particle size of 301±10.8 nm. Deposition of alternate polymers was accompanied by a reversal of surface potential (Fig. 2B), which indicated that a solid monolayer had been deposited. An abrupt rise in the liposome surface potential (from -8.66±0.68 to 39.1±0.43 mV) was observed after addition of the first (FA-CS) layer. However, the similar surface potential was restored upon addition of the second (PEG-ALG) layer.

Morphological analysis. TEM was used to observe the morphology and structure of the FRNPs directly. The blank NPs exhibited well-defined spherical shape with a smooth surface and small size (Fig. 2C). The FRNPs exhibited a rough surface and increased average diameter after the addition of polymers by LbL assembly (Fig. 2D): a darker phosphotungstic acid-stained core and a lesser-stained shell were visible. This indicated that the addition of polymer layers resulted in the formation of compact core-shell NPs.

Establishment of tumor xenograft animal model. Firstly, 

RT-qPCR was used to examine FR expression in the Bel7402, 

SW620 and A549 cancer cells. The results presented in Fig. 3A showed that among these 3 types of cancer cells, the Bel7402 cells expressed the highest level of FR, followed by the SW620 cells. The A549 cells exhibited the lowest expression level of FR. Subsequently, we developed certain types of tumor xenografts with these cancer cell lines by injecting the cell suspensions into mice and determined FR expression in the tumor tissue of these
FRNP group, the intensity value of the Bel7402 and SW620 tumor xenografts was significantly higher than that of the A549 tumor xenografts from 20 to 160 min post-injection (P=0.012). Until the time point of 160 min post-injection, the enhancement of the FRNPs in the Bel7402 tumor xenografts and SW620 tumor xenografts remained at a high level of intensity, and this
suggested that the FRNPs exhibited a longer duration of effective enhanced ultrasound imaging. In the blank NP groups, the mean grey value exhibited no significant difference among the 3 types of xenografts at all time points (P=0.694). According to the results of ultrasound imaging in vivo, the images from the FR overexpressing tumors (Bel7402 tumor xenografts and SW620 tumor xenografts) displayed a higher increased intensity value than the images from the low expressing tumors (A549 xenografts). However, we did not find similar situations such as these after the injection of blank NPs and Sonovue. These results revealed that the FRNPs achieved specific enhanced imaging for FR overexpressing tumors and the effects of tumor imaging were significantly superior to those of Sonovue at 40 min post-injection.

**Targeting ability and biodistribution of FRNPs in vivo.** The fluorescence images of Cy7-labeled FRNPs were obtained using the Kodak In-vivo Imaging System FX PRO at different time points following injection with Cy7-labeled FRNPs. The Cy7 fluorescence dye, which has absorption and emission maxima around 747 and 774 nm, belongs to the class of NIR fluorescence dyes. NIR fluorescence imaging has many advantages, including relatively minimal autofluorescence, low tissue absorption and scatter, which results in greater tissue penetration than visible optical fluorescent dyes for in vivo imaging applications within the 650-900 nm NIR window (29,30). Thus, the fluorescent images of Cy7-labeled nanoparticles can determine the in vivo biodistribution and tumor selective effect of nanoparticles (31-34).

The fluorescence imaging of xenografts were as shown in Fig. 7A, indicating the distribution of FRNPs and its aggregation in tumor region. At 1 and 5 min after the intravenous injection of the fluorescent particles, the images of xenografts were covered with different fluorescent signal strength and there were no differences in fluorescence intensity within tumor regions among the 3 types of xenografts. The fluorescence intensity of the tumor regions in the Bel7402 and SW620 tumor xenografts increased significantly from 30 min to 2 h post-injection, and high levels of fluorescence intensity remained until 12 h. By contrast, less tumor fluorescence accumulation was observed in the A549 xenografts at the same time points. The fluorescence intensity of the tumors and muscles was detected at the different time points in order to semi-quantitatively analyze the targeting ability of the FRNPs to the FR overexpressing tumor tissues. The average of TBR between the tumor and adjacent normal thigh muscle is shown in Fig. 7B.
To further determine the fluorescent signals in different tissues, the mice were sacrificed at 12 h post-injection and the heart, liver, spleen, lung, kidneys, intestines and tumors were excised, washed with PBS and exposed to fluorescence imaging. As shown in Fig. 8 for the ex vivo fluorescence imaging of different tissues, the fluorescent signal in the tumors of the Bel7402 and SW620 tumor xenografts was very strong, whereas little signal intensity was visible in the tumors of the A549 tumor xenografts. To semi-quantitatively analyze the targeting ability of the FRNPs, the fluorescence intensity in the tumors was measured. The average fluorescent signal intensity of the tumors excised from the Bel7402, SW620 and A549 tumor xenografts was $(2.4 \pm 0.1) \times 10^{10}$, $(2.3 \pm 0.02) \times 10^{10}$, $(1.24 \pm 0.03) \times 10^{10}$ photons/sec/mm$^2$ (the fluorescence images of tumors can be seen on the right side in the bottom row of Fig. 8A, B and C). The differences of fluorescent signal intensity among the 3 types of xenografts were statistically significant ($P=0.027$). These results were consistent with the outcomes from the in vivo ultrasound imaging. The ex vivo tumor imaging results also demonstrated that the FRNPs exhibited relatively high tumor-targeted distribution in the FR overexpressing tumors.

**Histological analysis.** To further verify the fluorescence imaging results and confirm the presence of FRNPs in tumor tissues, the frozen tissue slices of the tumor tissues were collected and fixed at 90 min post-injection of Cy7-labeled FRNPs (Fig. 9). Only a weak fluorescent signal, corresponding to autofluorescence was observed in the tumor slices of the control group. In the targeted group, we observed that the fluorescent signals of high intensity (red spots) were converged on some areas that seemed like the blood vessels of tumor tissues, whereas fluorescent signals of extravascular areas remained weak in the slices of A549 xenografts. By contrast, more and brighter fluorescent signals of extravascular areas in the slices of the Bel7402 xenografts and SW620 xenografts were observed. These results revealed that the FRNPs passed through the endothelial gap of the tumor blood vessel and combined with the tumor tissues. The targeting ability to FR overexpressing tumors and PEGylated surface against the ‘cleaning up’ by the reticuloendothelial system (RES) led to the accumulation of...
FRNPs in FR overexpressing tumors. The H&E-stained slices of tumor tissue were observed and typical pathological mitotic figures were evident and did not exhibit any significant differences between the 2 groups.

Discussion

With the development of contrast agents, contrast-enhanced ultrasonography has played an important role in the detection and differentiation of tumors. Although many types of ultrasound contrast agents have been developed for clinical application, some clinical studies have indicated that the contrast agents currently used are limited by insufficient sensitivity and specificity (1,4,35).

Nowadays, the emerging of molecular imaging introduces a new avenue for tumor detection at the molecular level with ultrasonography. However, the application of molecular ultrasound imaging is required to develop nanosized contrast agents, of which the particle size is smaller than the contrast agents recently used (7,36).

Currently, PFOB nanoparticles have been reported to be applied to molecular ultrasound imaging in vivo, including several molecular targeted medicine applications (37-40). The application of PFOB nanoparticles into the field of ultrasonography has been limited to low-intensity of ultrasound reflection due to nanosized particle size and the nanoparticles may also be less liable to non-specific signal enhancement events since larger concentrations (more binding events) are required to produce conspicuity (41,42).

Furthermore, FR is highly expressed in various human malignancies and it has been served as a potential targeted ligand for tumor imaging and antitumor therapy due to the high affinity to bind with FA. Thus, in this study, we conducted a constructive attempt to apply the polymers of FA-CS and PEG-ALG to the preparation of the FR overexpressed tumor targeted nanoparticles (FRNPs) by using the LbL assembly technique, which maintained the advantages of FR-targeting affinity and resistance against the macrophage of RES due to PEG modification.

In this study, the targeted shell consisted of FA-CS and PEG-ALG, which were easily obtained by the carbodiimide method and did not need complex modifications. We introduced the LbL assembly technique to the process of core-shell enveloping, which improved the quality and effectiveness of targeted shell. As shown in Fig. 2A, the particle size decreased from 244.7±6.0 to 217.6±5.6 nm and the surface potential was reversed (from 39.1±0.4 to -21.6±1.3) after the first addition of PEG-ALG (layer 2). This indicated that a mesh shell on the surface of PFOB liposome was forming by the strong ionic electrostatic interaction between PEG-ALG and FA-CS. In the TEM images (Fig. 2D), we could see that FRNPs exhibited a rough surface and retained larger particle size, whereas the blank NPs (PFOB liposomes) main-
tained a smooth surface and a small size. Although the different layers could not distinguished clearly, a darker phosphotungstic-acid-stained core and a lesser-stained shell were visible. After the LbL assembly was completed, the FRNPs maintained FR-targeting function (FA modified) and solvent stability (the electrostatic repulsive force and the PEGylated polymers that further extend the repulsive force and prevent aggregation). In the assembly process, we made an attempt to keep the particle size in an optimal range by careful adjustment of the polymer ratios.

In the targeted binding assay in vitro, the FRNPs were specifically taken up by the Bel7402 and SW620 cancer cells (FR overexpressing cancer cell lines). Subsequently, we investigated the ultrasonography for xenograft models and found that the FRNPs obtained specific ultrasound enhanced imaging for FR overexpressing tumors. Although the enhancement of FRNPs was slightly weaker than that of Sonovue, it maintained a longer enhanced duration in FR overexpressing tumors. Furthermore, in the fluorescence imaging of the xenograft models, the ultrasound imaging results of the FRNPs were confirmed. As shown in Fig. 7, that fluorescence intensity in the FR overexpressing tumor region was significantly stronger at 30 min post-injection, and the ex vivo fluorescence imaging of tumors and other organs (Fig. 8) revealed that the intestines and tumors possessed a higher intensity of fluorescent signal. These results indicated that FRNPs could accumulate in FR overexpressed tumor and pass out through the endothelial gap of tumor blood vessel for targeting to FR overexpressed tumors.

In conclusion, in this study, we developed a novel strategy of ultrasonic nanoparticles modified with FA and PEG for FR overexpressing tumor imaging. FRNPs were successfully synthesized with the LbL assembly technique and maintained suitable physicochemical properties. Our data illustrated that FRNPs exhibited a respectable ability to target the certain tumors in vitro and in vivo. At present, there are certain deficiencies and limits in tumor-targeted imaging. FRNPs may thus have potential for early diagnosis and targeted therapy of FR overexpressing tumors. The nanoparticles and these methods of preparation may prove to be useful for further medical and biological applications.

Acknowledgements

The present study was supported by grants from the Social Development Major Project in Ningbo, China (no. 2012C5013).

References

1. Perera RH, Hernandez C, Zhou H, Kota P, Burke A and Exner AA: Ultrasound imaging beyond the vasculature with new generation contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7: 593-608, 2015.
2. Cascio S, Soloperto G, Greco A, Casciero E, Franchini R and Conversano F: Effectiveness of functionalized nanosystems formultimodal functionalized imaging and sensing in medicine. IEEE Sens J 6: 2305-2312, 2013.
3. Maeda H, Wu J, Sawa T, Matsumura Y and Horii K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65: 271-284, 2000.
4. Hahn MA, Singh AK, Sharma P, Brown SC and Moudgil BM: Nanoparticles as contrast agents for in-vivo bioimaging: Current status and future perspectives. Anal Bioanal Chem 399: 3-27, 2011.
5. Koyabashi H, Turkhey B, Watanabe R and Choyke PL: Cancer drug delivery: Considerations in the rational design of nanosized bioconjugates. Bioconjug Chem 25: 2093-2100, 2014.
6. Orocio-Rodriguez E, Ferro-Flores G, Santos-Cuevas CL, Ramirez FM, Ocampo-Garcia BE, Azorin-Vega E and Sanchez-Garcia FM: Two novel nanosized radiolabeled analogues of somatostatin for neuroendocrine tumor imaging. J Nanosci Nanotechnol 15: 4159-4169, 2015.
7. Toy R, Bauer L, Holmes C, Ghaghadia KB and Karanthanas E: Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev 76: 79-97, 2014.
8. Wilson KE, Wang TY and Willmann JK: Acoustic and photoacoustic molecular imaging of cancer. J Nucl Med 54: 1851-1854, 2013.
9. Gessner R and Dayton PA: Advances in molecular imaging with ultrasound. Mol Imaging 9: 117-127, 2010.
10. Zhao R, Mathery LH and Goldman ID: Membrane transporters and folate homeostasis: Intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11: e4, 2009.
11. Shen F, Wu M, Ross JF, Miller D and Ratnam M: Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: Protein characterization and cell type specificity. Biochemistry 34: 5660-5665, 1995.
12. Kane MA: The role of folates in squamous cell carcinoma of the head and neck. Cancer Detect Prev 29: 46-53, 2005.
13. Hartmann LC, Keene LY, Lingle WL, Christianson TJ, Varghese B, Hillman B, Brown AL and Low PS: Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121: 938-942, 2007.
14. O’Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Somers EB and Vachani A: Folate receptor alpha expression in lung cancer: Diagnostic and prognostic significance. Oncotarget 3: 414-425, 2012.
15. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS and Leamon CP: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338: 284-293, 2005.
16. Assafar YG, Leamon CP and Reddy JA: The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat 17: 89-95, 2014.
17. Wu M, Gunning W and Ratnam M: Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in uterine, cervix. Cancer Epidemiol Biomarkers Prev 8: 775-782, 1999.
18. Kallii KR, Oberg AL, Keene LY, Christianson TJ, Low PS, Knutson KL and Hartmann LC: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108: 619-626, 2008.
19. Bueno R, Appasani K, Mercer H, Lester S and Sugarbaker D: The α folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122: 225-233, 2001.
20. Lu Y, Sega E and Low PS: Folate receptor-targeted immuno-therapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer 116: 710-719, 2005.
21. Siafaka P, Betiu M, Tsolou A, Angelou E, Agianian B, Koffa M, Chatidou S, Karavas E, Avgoustakis K and Bikaris D: Synthesis of folate–polygelysed polyester nanoparticles encapsulating inaxabipelone for targeting folate receptor overexpressing breast cancer cells. J Mater Sci Mater Med 26: 275, 2015.
22. Liu X, Zhao J, Guo D, Wang Z, Song W, Chen W and Zhou J: Synthesis and evaluation of perfluorooctylbromide nanoparticles modified with a folate receptor for targeting ovarian cancer: in vitro and in vivo experiments. Int J Clin Exp Med 8: 10122-10131, 2015.
23. Zhou J, Romero G, Rojas E, Ma L, Moya S and Gao C: Layer by layer chitosan/alginate coatings on poly(ethylene-co-glycolide) nanoparticles for antifouling protection and Folic acid binding to achieve selective cell targeting. J Colloid Interface Sci 345: 241-247, 2010.
24. Elhissi AM, O’Neill MA, Roberts SA and Taylor KM: A calorimeter study of dimethylsphosphatidylcholine phase transitions and steroid-liposome interactions for liposomes prepared by thin film and protoliposome methods. Int J Pharm 250: 124-130, 2006.
25. Salem HF, Ahmed SM, Hassaballah AE and Omar MM: Targeting brain cells with gluthathione-modulated nanoliposomes: In vitro and in vivo study. Drug Deliv 18: 3905-3927, 2011.
26. Barnett BP, Ruiz-Cabello J, Hoiu P, Oosterkerk R, Shambolt MJ, Lauzon C, Walczak P, Gilson WD, Chacko VP, Kraitchman DL, et al: Use of perfluorocarbon nanoparticles for non-invasive multimodal cell tracking of human pancreatic islets. Biomaterials 35: 9984-9994, 2014.
27. Kim J, Lee CM, Jeong HJ and Lee KY: In vivo tumor accumulation of nanoparticles formed by ionic interaction of glycol chitosan and fatty acid ethyl ester. J Nanosci Nanotechnol 11: 1160-1166, 2011.

28. Alencar H, Funovics MA, Figueiredo J, Sawaya H, Weissleder R and Mahmood U: Colonic adenocarcinomas: Near-infrared microcatheter imaging of smart probes for early detection - study in mice. Radiology 244: 232-238, 2007.

29. Hawrysz DJ and Sevick-Muraca EM: Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia 2: 388-417, 2000.

30. Zheng C, Zheng M, Gong P, Jia D, Zhang P, Shi B, Sheng Z, Ma Y and Cai L: Indocyanine green-loaded biodegradable tumor targeting nanoprobes for in vitro and in vivo imaging. Biomaterials 33: 5603-5609, 2012.

31. Hama Y, Koyama Y, Choyke PL and Kobayashi H: Two-color in vivo dynamic contrast-enhanced pharmacokinetic imaging. J Biomed Opt 12: 034016, 2007.

32. Nakamura T, Kawano K, Shiraishi K, Yokoyama M and Maitani Y: Folate-targeted gadolinium-lipid-based nanoparticles as a bimodal contrast agent for tumor fluorescent and magnetic resonance imaging. Biomaterials 35: 5603-5609, 2012.

33. Chung EJ, Milnar LB, Sugimoto MJ, Nord K, Roman BB and Tirrell M: In vivo biodistribution and clearance of peptide amphiphile micelles. Nanomedicine 11: 479-487, 2015.

34. Chung EJ, Cheng Y, Morshed R, Nord K, Han Y, Wegscheid ML, Auffinger B, Wainwright DA, Lesniak MS and Tirrell MV: Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials 35: 1249-1256, 2014.

35. Blomqvist L, Carlsson S, Gjerstorff P, Heinze G, Hultcrantz M, Mejare I and Andren O: Limited evidence for the use of imaging to detect prostate cancer: A systematic review. Eur J Radiol 83: 1601-1606, 2014.

36. Sivasubramanian M, Hsia Y and Lo LW: Nanoparticle-facilitated functional and molecular imaging for the early detection of cancer. Front Mol Biosci 1: 15, 2014.

37. Giraudet C, Gefroy F, Mériaux S, Boumezbeur F, Robert P, Port M, Robic C, Le Bihan D, Lethimonnier F and Valette J: 19F molecular MR imaging for detection of brain tumor angiogenesis: In vivo validation using targeted PF0B nanoparticles. Angiogenesis 16: 171-179, 2013.

38. Vu-Quang H, Vinding MS, Xia D, Nielsen T, Ullisch MG, Dong M, Nielsen NC and Kjems J: Chitosan-coated poly(lactic-co-glycolic acid) perfluorooctyl bromide nanoparticles for cell labeling in (19)F magnetic resonance imaging. Carbohydr Polym 136: 936-944, 2016.

39. Watanabe T, Kimura Y and Ono T: Microfluidic fabrication of monodisperse polylactide microcapsules with tunable structures through rapid precipitation. Langmuir 29: 14082-14088, 2013.

40. Decato S, Bemis T, Madsen E and Meozzi S: Synthesis and characterization of perfluoro-tert-butyl semifluorinated amphiphilic polymers and their potential application in hydrophobic drug delivery. Polym Chem 5: 6461-6471, 2014.

41. Marsh JN, Hall CS, Scott MJ, Fuhrhop RW, Gaffney PJ, Wickline SA and Lanza GM: Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. IEEE Trans Ultrason Ferroelectr Freq Control 49: 29-39, 2002.

42. Marsh JN, Partlow KC, Abendson DR, Scott MJ, Lanza GM and Wickline SA: Molecular imaging with targeted perfluorocarbon nanoparticles: Quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med Biol 33: 950-958, 2007.